XLO logo

XILIO THERAPEUTICS INC

XLONASDAQ
🏆 #4416 by market capUS Equity
$712.86▲ $8.06 (+1.13%)
Simulated price
🔔
Track XLO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.1%
7d▲ 7820.7%
14d▲ 7829.5%
30d▲ 7803.1%
ytd▲ 7809.2%
1y▲ 5681.5%
🏦Market Cap
$54M
Small Cap
📈Revenue Growth (YoY)
+327.3%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
0.9x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$702.58 – $723.70
52-Week Range
$6.47 – $12.74
Volume
$2.15B
Avg Volume
$1.77B
Shares Outstanding
6.0M
Next Earnings
Nov 13, 2026

Fundamentals Snapshot

Annual Revenue
$44M
Last Q Revenue
$19M
P/E Ratio
—
P/S Ratio
0.9x
EPS (TTM)
$-1.54
Dividend Yield
—
Dilution (1yr)
+1709.4%

Why Investors Own XLO

  • ✓High-growth profile — revenue up +39.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 28% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

XLO logo

XILIO THERAPEUTICS INC

XLO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$44M▲ +589.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.5%▼ −3.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$42M▼ −30.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▼ −70.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
83.6M▲ +1709.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$131M▲ +$83M YoY
StockOtter · stockotter.space

About XILIO THERAPEUTICS INC

Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$904.20
▲ +26.8% Upside
High Target$1,074.36
Low Target$758.97
Based on 40 analysts

Latest News & Updates

🚀
Barron’s·2h ago

XILIO THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift XLO price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

XILIO THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.